2024 ESMO丨消化系统肿瘤领域LBA和Oral一文汇总
*仅供医学专业人士阅读参考
消化系统肿瘤相关摘要标题速递
撰文丨鹿其临
2024年9月13日-17日，欧洲肿瘤内科学会（ESMO）年会将于在西班牙巴塞罗那召开，作为肿瘤内科最高规模的国际盛会，涉及肺癌、乳腺癌、消化道肿瘤、泌尿生殖系统肿瘤等领域的多项研究届时皆将披露最新进展。
目前，ESMO官网已经公布本次入选大会的LBA、Oral（O）和Mini oral（MO）标题，医学界特将部分消化系统肿瘤相关摘要标题进行整理，分为胃癌、肠癌、肝细胞癌、胰腺癌、胃肠道间质瘤，以飨读者。（注：本文不分先后顺序）
胃癌
摘要号：LBA58
A randomized phase III trial of perioperative chemotherapy (periop CT) with or without preoperative chemoradiotherapy (preop CRT) for resectable gastric cancer (AGITG TOPGEAR): final results from an intergroup trial of AGITG, TROG, EORTC and CCTG
随机III期AGITG-TOPGEAR试验：围术期化疗（围术期CT）±术前放化疗（术前CRT）治疗可切除胃癌，来自AGITG、TROG、EORTC和CCTG组间试验的最终结果
汇报专家：Trevor Leong（澳大利亚・墨尔本）
摘要号：LBA59
Modified FOLFOX plus/minus Nivolumab and Ipilimumab vs FLOT plus Nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction – Final Results of the IKF-AIO-Moonlight trial
IKF-AIO-Moonlight试验的最终结果：改良FOLFOX±纳武利尤单抗＋伊匹木单抗 vs FLOT+纳武利尤单抗治疗既往未经治的晚期或转移性胃或胃食管交界（G/GEJ）腺癌患者
汇报专家：Sylvie Lorenzen（德国・慕尼黑）
摘要号：LBA60
Phase 3 study of SHR-1701 versus placebo in combination with chemo as first-line (1L) therapy for HER2-negative gastric/gastroesophageal junction adenocarcinoma (G/GEJA)
III期研究：SHR-1701 vs安慰剂联合化疗一线治疗HER2阴性G/GEJ腺癌
汇报专家：彭智（北京大学肿瘤医院）
摘要号：1400O
Final overall survival for the phase 3, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic G/GEJ adenocarcinoma
III期KEYNOTE-811研究的最终OS数据：帕博利珠单抗+曲妥珠单抗+化疗治疗HER2+晚期、不可切除或转移性G/GEJ腺癌
汇报专家：Yelena Y. Janjigian（美国・纽约）
摘要号：609O
CLDN18.2 targeted antibody-drug conjugate (ADC), SHR-A1904, in patients (pts) with gastric/gastroesophageal junction cancer (GC/GEJC): a phase 1 study
I期研究：靶向CLDN18.2 ADC药物，SHR-A1904用于G/GEJ癌患者
汇报专家：徐瑞华（中山大学肿瘤防治中心）
摘要号：1401O
Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03)
DESTINY-Gastric03（DG-03）研究：德曲妥珠单抗（T-DXd）单药治疗及联合治疗晚期/转移性HER2阳性（HER2+）食管、G/GEJ腺癌患者
汇报专家：Yelena Y. Janjigian（美国・纽约）
摘要号：1402MO
An international study evaluating pathological response to guide adjuvant FLOT chemotherapy in gastroesophage
一项国际研究：评估病理反应以指导胃食管癌的辅助FLOT化疗
汇报专家：Margaret M. Lee（澳大利亚・盒子山）
肠癌
结肠癌
摘要号：LBA24
Neoadjuvant immunotherapy in locally advanced MMR-deficient colon cancer: 3-year disease-free survival from NICHE-2
局部晚期dMMR结肠癌的新辅助免疫疗法：来自NICHE-2研究的3年无病生存期（DFS）
汇报专家：Myriam Chalabi（荷兰・阿姆斯特丹）
摘要号：63O
Transcriptional features of stage IIT4N0/III colon cancer associated with residual disease and ctDNA status after surgery in the PEGASUS trial
在PEGASUS试验中，与术后残留疾病和ctDNA状态相关的II期T4N0/III期结肠癌的转录特征
汇报专家：Enzo Medico（意大利・坎迪奥洛）
摘要号：503O
Neoadjuvant nivolumab (nivo) plus relatlimab (rela) in MMR-deficient colon cancer: Results of the NICHE-3 study
新辅助纳武利尤单抗（nivo）联合relatlimab（rela）治疗dMMR结肠癌患者：NICHE-3研究结果
汇报专家：Peter G. De Gooyer（荷兰・阿姆斯特丹）
摘要号：512O
Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients – The Phase III, Prospective-Randomized Placebo-Controlled Multicenter SAKK 41/13 Trial
阿司匹林辅助治疗PIK3CA突变结肠癌患者——III期、前瞻性随机安慰剂对照的多中心SAKK 41/13试验
汇报专家：Ulrich Güller（瑞士・图恩湖）
结直肠癌
摘要号：LBA25
Randomized Phase III trial of Ramucirumab in combination with TAS102 (Trifluridin/Tipiracil) vs. TAS102 monotherapy in heavily pretreated metastatic colorectal cancer: The RAMTAS/IKF643 trial of the German AIO (AIO-KRK-0316)
随机III期德国AIO（AIO-KRK-0316）的RAMTAS/IKF643试验： 雷莫西尤单抗联合TAS102（Trifluridin/Tipiracil）vs TAS102单药治疗既往接受治疗后复发转移性结直肠癌（mCRC）
汇报专家：Stefan Kasper-Virchow（德国・埃森）
摘要号：LBA26
SOLARIS (Alliance A021703): A multicenter double-blind phase III randomized clinical trial (RCT) of vitamin D (VitD) combined with standard chemotherapy plus bevacizumab (bev) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC)
SOLARIS（Alliance A021703）：一项多中心双盲III期随机临床试验（RCT），探索维生素D（VitD）联合标准化疗、贝伐珠单抗（bev）治疗既往未经治疗的mCRC患者
汇报专家：Kimmie Ng（美国・波士顿）
摘要号：502O
Pembrolizumab in combination with CAPOX and bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: preliminary results of FFCD 1703 POCHI trial
帕博利珠单抗联合CAPOX和贝伐珠单抗治疗微卫星稳定mCRC和高免疫浸润患者：FFCD 1703 POCHI试验的初步结果
汇报专家：David Tougeron（法国・普瓦捷）
摘要号：504O
IMHOTEP Phase II trial of neoadjuvant pembrolizumab in dMMR/MSI tumors: results of the colorectal cancer cohort
IMHOTEP II期试验结果：帕博利珠单抗新辅助治疗dMMR/MSI CRC患者
汇报专家：Christelle De la Fouchardiere（法国・马赛）
摘要号：505O
Sotorasib (soto), panitumumab (pani) and FOLFIRI in the first-line (1L) setting for KRAS G12C–mutated metastatic colorectal cancer (mCRC): Safety and efficacy analysis from the phase 1b CodeBreaK 101 study
索托拉西布（soto）、panitumumab（pani）和FOLFIRI在KRAS G12C突变的mCRC一线治疗中的应用：CodeBreaK 101 Ib期研究的安全性和有效性分析
汇报专家：Salvatore Siena（意大利・米兰）
摘要号：506O
Evaluation of risk of disease progression in first-line therapy of unresected metastatic colorectal cancer to guide intervals of radiological assessment- an analysis of eleven randomized trials by AIO and GONO
评估未切除的mCRC一线治疗中的疾病进展风险，以指导放射学评估间隔——一项由AIO和GONO进行的11项随机试验分析
汇报专家：Marco M. Germani（意大利・比萨）
摘要号：507O
Impact of lean body mass-based oxaliplatin dosage on neurotoxicity in adjuvant treatment of stage III colorectal cancer. Final results of the phase II randomized multicenter LEANOX trial
以轻体重计算的奥沙利铂剂量对III期结直肠癌辅助治疗中神经毒性的影响：LEANOX II期随机多中心试验的最终结果
汇报专家：Eric Assenat（法国・蒙彼利埃）
摘要号：511MO
Third line rechallenge with cetuximab (Cet) and irinotecan in circulating tumor DNA (ctDNA) selected metastatic colorectal cancer (mCRC) patients: the randomized phase II CITRIC trial
在循环肿瘤DNA（ctDNA）筛选的mCRC患者中，第三次使用西妥昔单抗（Cet）和伊立替康再挑战：随机II期CITRIC试验
汇报专家：Cristina Santos Vivas（西班牙・卢斯皮塔莱特德略夫雷加特）
摘要号：513MO
Amivantamab plus FOLFOX or FOLFIRI in metastatic colorectal cancer: Results from OrigAMI-1, an open-label, phase 1b/2 study
埃万妥单抗联合FOLFOX或FOLFIRI治疗mCRC患者：来自一项开放标签、Ib/II期OrigAMI-1研究结果
汇报专家：Filippo Pietrantonio（意大利・米兰）
摘要号：514MO
The efficacy and safety of ivonescimab with or without ligufalimab in combination with FOLFOXIRI as first-line (1L) treatment for metastatic colorectal cancer (mCRC)
依沃西单抗±ligufalimab+FOLFOXIRI一线治疗mCRC的疗效和安全性
汇报专家：邓艳红（中山大学附属第六医院）
摘要号：515MO
Encorafenib + Cetuximab (EC) + FOLFIRI for BRAF V600E-Mutant Metastatic Colorectal Cancer (mCRC): Updated Results From the BREAKWATER Safety Lead-In (SLI)
Encorafenib+西妥昔单抗（EC）+FOLFIRI治疗BRAF V600E突变mCRC ：来自BREAKWWATER安全性先行试验（SLI）最新结果
汇报专家：Josep Tabernero（西班牙・巴塞罗纳）
摘要号：516MO
Zanidatamab (Zani) + Chemotherapy (CT) in First-Line (1L) Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Advanced/Metastatic Colorectal Cancer (mCRC)
Zanidatamab（Zani）+化疗（CT）一线治疗HER2阳性晚期/mCRC
汇报专家：Sun Young Rha（韩国・首尔）
摘要号：518MO
Update analysis of the randomized phase II study comparing FOLFIRI plus (RAM) versus FOLFOXIRI plus RAM as first-line treatment for patients with metastatic colorectal cancer: WJOG9216G (RECAST)
随机II期WJOG9216G（RECAST）研究的最新分析：FOLFIRI+雷莫西尤单抗（RAM）vs FOLFXIRI+RAM一线治疗mCRC患者
汇报专家：Kentaro Yamazaki（日本・静冈）
直肠癌
摘要号：508MO
Organ preservation in early rectal adenocarcinoma: 5-year results of the randomized opera trial
早期直肠腺癌的器官保留：Opera随机手术试验的5年结果
汇报专家：Syrine Ben Dhia（法国・尼斯)
摘要号：509O
Total Neoadjuvant Treatment (TNT) with Non-Operative Management (NOM) for Proficient Mismatch Repair Locally Advanced Rectal Cancer (pMMR LARC): First Results of NO-CUT Trial
对于熟练pMMR局部晚期直肠癌（pMMR LARC）采用全程新辅助治疗（TNT）与非手术治疗（NOM）：NO-CUT试验的首次结果
汇报专家：Alessio Amatu（意大利・米兰）
肝细胞癌
摘要号：LBA3
Transarterial Chemoembolization (TACE) With or Without Lenvatinib (len) + Pembrolizumab (pembro) for Intermediate-Stage Hepatocellular Carcinoma (HCC): Phase 3 LEAP-012 Study
经动脉化疗栓塞（TACE）±仑伐替尼（len）+帕博利珠单抗（pembro）治疗中期肝细胞癌（HCC）：III期LEAP-012研究
汇报专家：Josep Llovet（西班牙・巴塞罗纳）
摘要号：LBA38
Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy in first-line (1L) treatment of advanced hepatocellular carcinoma (aHCC): a randomized, open-label, phase 2/3 study (DUBHE-H-308)
Iparomlimab和tuvonralimab（QL1706）联合贝伐珠单抗和/或化疗用于晚期HCC 的一线治疗： 一项随机、开放标签、II/III期研究（DUBHE-H-308）
汇报专家：秦叔逵（南京天印山医院）
摘要号：LBA39
Updated efficacy and safety data from IMbrave050: Phase 3 study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC)
IMbrave050的最新疗效和安全性数据：阿替利珠单抗（atezo）+贝伐珠单抗（bev）辅助治疗与主动监测在切除或消融的高危HCC患者的III期研究
汇报专家：Adam Yopp（美国・达拉斯）
摘要号：LBA40
Primary results from the phase III ALTN-AK105-III-02 study: Anlotinib plus penpulimab versus sorafenib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)
III期ALTN-AK105-III-02研究的主要结果：派安普利单抗vs索拉非尼联合安罗替尼一线治疗aHCC
汇报专家：周俭（复旦大学附属中山医院）
摘要号：947MO
Five-year overall survival (OS) and OS by tumour response measures from the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
III期HIMALAYA研究：tremelimumab联合度伐利尤单抗治疗uHCC的的5年总生存期（OS）和肿瘤反应测量的OS
汇报专家：Lorenza Rimassa（意大利・罗扎诺）
摘要号：965MO
Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): expanded analyses from CheckMate 9DW
纳武利尤单抗（NIVO）联合伊匹木单抗（IPI）vs仑伐替尼（LEN）或索拉非尼（SOR）作为不可切除HCC的一线治疗：CheckMate 9DW的扩展分析
汇报专家：Thomas Decaens（法国・拉特龙什）
胰腺癌
摘要号：LBA62
Preoperative modified FOLFIRINOX (mFOLFIRINOX) with or without chemoradiation (CRT) in borderline resectable pancreatic cancer (BRPC): results from the randomized phase II trial PANDAS/PRODIGE 44
可边缘切除胰腺癌（BRPC）术前改良FOLFIRINOX（mFOLFIRINO）±放化疗（CRT）：PANDAS/PRODIGE 44随机II期试验结果
汇报专家：Aurélien Lambert（法国・旺多洛夫南锡）
摘要号：LBA63
A randomized phase I/II study of second line treatment with liposomal irinotecan and S-1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer following gemcitabine-based chemotherapy
伊立替康脂质体联合S-1 vs伊立替康脂质体联合5-氟尿嘧啶二线治疗吉西他滨化疗后转移性PC患者的随机I/II期研究
汇报专家：Anne M. Gehrels（荷兰・阿姆斯特丹）
摘要号：608O
Preliminary safety and clinical activity of ASP3082, afirst-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC)
ASP3082（first-in-class的KRAS G12D选择性蛋白质降解剂）在患有晚期PC、CRC和非小细胞肺癌（NSCLC）的成人中的初步安全性和临床活性
汇报专家：Wungki Park（美国・纽约）
摘要号：1504MO
Phase 2 Trial of Pembrolizumab and OLApaRib (POLAR) Maintenance for Select Patients (pts) with Metastatic Pancreatic Cancer (mPC) with (A) Homologous Recombination Deficiency (HRD), (B) non-core HRD (ncHRD) and (C) Exceptional Response to Platinum
帕博利珠单抗和奥拉帕利（POLAR）维持治疗特定转移性PC患者的II期试验：患者患有（A）同源重组缺陷（HRD），（B）非核心HRD（ncHRD）和（C）对铂的异常反应
汇报专家：Wungki Park（美国・纽约）
胃肠道间质瘤
摘要号：LBA79
LENVAGIST - A multicentre, comparative, placebo (P)-controlled, double-blinded, phase II study of the efficacy of Lenvatinib (L) in patients with advanced GIST after failure of imatinib and sunitinib
LENVAGIST：一项多中心、对照、安慰剂（P）对照、双盲、II期研究，探索仑伐替尼治疗伊马替尼和舒尼替尼失败后晚期胃肠道间质瘤（GIST）患者的疗效
汇报专家：Axel Le Cesne（法国・犹太城）
摘要号：1722MO
Updated efficacy results of olverembatinib (HQP1351) in patients with succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and potential mechanisms of action (MOA)
奥雷巴替尼（HQP1351）治疗琥珀酸脱氢酶（SDH）缺陷型GIST患者的最新疗效结果和潜在作用机制（MOA）
汇报专家：邱海波（中山大学肿瘤防治中心）
摘要号：1723MO
Axitinib plus avelumab in patients with unresectable/metastatic gastrointestinal stromal tumor (GIST) after failure of standard therapy: single-arm phase II study (AXAGIST)
阿昔替尼联合avelumab治疗接受标准治疗失败后不可切除/转移性GIST患者：单臂II期研究（AXAGIST）
汇报专家：Piotr Rutkowski（波兰・华沙）
备注：如有遗漏或任何问题，请给我们留言。
更多ESMO精彩内容，关注医学界肿瘤频道。
责任编辑：Sheep
*医学界力求其发表内容专业、可靠，但不对内容的准确性做出承诺；请相关各方在采用或以此作为决策依据时另行核查。